RXRX RECURSION PHARMACEUTICALS, INC.
Company Analysis
Latest News
Recursion's second quarter shows pipeline progress with a Genentech milestone and reduced FY2026 expense guidance despite a revenue miss.
Recursion Pharmaceuticals reported second quarter 2026 revenue of $7.7 million, missing analyst estimates, while its EPS loss of $0.25 was in line with...
🟢 Recursion Pharmaceuticals is trading 5% up today ahead of Q2 earnings and a broader biotech rally
Recursion Pharmaceuticals is trading 5% up at $3.35 as investors position themselves ahead of the company's second-quarter results scheduled for August 5,...
Recursion Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Recursion Pharmaceuticals to report a Q2 2026 consensus revenue of $10.97 million and an EPS loss of $0.25, with the stock currently trading...
🟢 Recursion Pharmaceuticals is trading 5.2% up today amid a broader market rally
Recursion Pharmaceuticals is trading 5.2% up at $3.15 today, tracking a broader market rally as major indices gain more than 1%. • The move comes amid a...
🟢 Recursion Pharmaceuticals is trading 5.2% up today on a technical rebound from recent weakness
Recursion Pharmaceuticals is trading 5.2% up today at $3.04 as the stock stages a modest rebound from recent weakness despite a lack of fresh company-specific...
Recursion Pharma Stock Slides After Insider Files Intent to Sell Shares
Recursion Pharmaceuticals (NASDAQ: RXRX) shares fell more than 7% on Thursday, July 16. An insider filed a Form 144 with the SEC. The filing indicated an...
AI Drug Discovery Faces Investor Reality Check Over Long Timelines
Investor skepticism is growing over the timeline for returns from AI in drug discovery, creating a disconnect with Wall Street's expectations. [1, 5] While AI...
🔴 Recursion Pharmaceuticals is trading 5.1% down today with no clear catalyst
Recursion Pharmaceuticals is trading at $3.14 (5.1% down) today amid a lack of fresh, company-specific news or major announcements directly tied to the...
🔴 Recursion Pharmaceuticals is trading 5.1% down today amid a broader biotech sector pullback
Recursion Pharmaceuticals is trading at $3.38 (5.1% down) amid a broader pullback in high-beta biotech and risk assets. • The move aligns with a decline in...
🔴 Recursion Pharmaceuticals Drops 4.9% Following Director Share Sale
Recursion Pharmaceuticals is trading at $3.58 (-4.92%) as of July 10, 2026. This decline follows reports of Director Blake Borgeson selling 40,000 shares on...
🟢 Recursion Pharmaceuticals Rises 4.6% on ARK Invest Buying and Russell Index Inclusion
Recursion Pharmaceuticals is trading at $3.89 (up 4.6%) today, buoyed by recent positive developments. • ARK Invest significantly increased its holdings in...
🔴 RXRX is trading 4% down today following recent insider selling filing and broader market downturn
• RXRX is trading 4% down today at $3.69, impacted by a recent SEC filing (Form 144 dated July 7, 2026) signaling planned insider share sales by CEO...
🟢 RXRX is trading 5.7% up today on ongoing AI drug discovery momentum
RXRX is trading 5.7% up now at $3.88, extending a week-long run of steady gains. The move appears driven by continued positive sentiment around its AI-driven...
🟢 RXRX is trading 5% up today on continued momentum in AI-driven drug discovery sentiment
RXRX is trading 5% up at $3.85 as the stock continues to build on a series of incremental gains over the past week, moving higher despite slight weakness in...
🟢 RXRX is trading 5.4% up today on ARK Investment buying and high short interest
RXRX is trading 5.4% up at $3.71 following renewed focus on institutional accumulation and heavy short positioning. • Recent disclosures highlighted fresh ARK...
🟢 RXRX is trading 5.2% up today on fresh ARK buying and elevated short interest
RXRX is trading 5.2% up at $3.52 following renewed attention on institutional interest and significant short positioning. • Recent disclosures revealed that...
Cathie Wood’s ARK buys 260,000 Recursion shares, backing AI drug discovery
ARK Investment acquired 260,000 shares of Recursion Pharmaceuticals. The transaction occurred on June 24, 2026. This purchase signals a strong vote of...
🟢 RXRX is trading 6.2% up today on short-squeeze speculation and high short interest
RXRX is trading 6.2% up at $3.35 as market participants weigh a potential short-squeeze narrative in the AI-driven drug discovery space against heavy short...
🟢 Recursion Pharmaceuticals Inc is trading 6.0% up today driven by a broader risk-on market rally
Recursion Pharmaceuticals Inc is trading at $3.34 (+6.03%) following a strong opening session that aligns with a broad risk-on rally in U.S. equities. • Major...
🔴 Recursion Pharmaceuticals Inc is trading 5.6% down today as macro jitters drive rotation out of growth and AI stocks
Recursion Pharmaceuticals Inc is trading 5.6% down today at $3.04 as investors rotate out of higher-risk growth and AI-related names following recent macro and...